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Abstract 
Novel fourth generation screening and confirmatory human immunodeficiency virus (HIV) assays are now com-
mercially available and incorporated into new diagnostic algorithms. We report two cases involving a total of three 
patients which highlight the spectrum of false positivity for both the Abbott Architect p24 antigen/antibody assay 
and the confirmatory Multispot antibody differentiation test. We then discuss the mechanisms for false positivity and 
the associated clinical conditions or laboratory scenarios that may predispose to inaccurate interpretation.
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Background
HIV continues to pose a significant worldwide burden 
of morbidity and mortality. The advent of anti-retroviral 
therapy (ART) led to a paradigm shift of care and mark-
edly improved outcomes in patients with HIV. Neverthe-
less, the global prevalence of HIV remains staggeringly 
high, and was estimated at 35.3 million in 2012 [1]. 
Additionally, despite multi-disciplinary advances in pre-
vention and treatment algorithms, nearly 40,000 new 
cases of HIV are reported annually in the United States 
[2]. Thus, timely detection of HIV infection, particularly 
when viremia and transmissibility are high, is of consid-
erable importance in continued efforts in both treatment 
and prevention of new infections. Novel fourth genera-
tion screening and confirmatory assays are now com-
mercially available and incorporated into new diagnostic 
algorithms [3]. We report two cases involving a total of 
three patients which highlight the spectrum of false posi-
tivity despite the introduction of these assays, and review 
the mechanisms and associations with false positivity 
that remain critical for the clinician’s interpretation.
Case 1
A 33  year old man presented with tender lateral neck 
swelling, cramping abdominal pain, and night sweats. 
He reported intra-nasal cocaine use and an instance 
of unprotected heterosexual contact in the preceding 
month. He denied intravenous drug use. On admission, 
he was afebrile with normal vital signs. His physical 
examination was significant for bulky adenopathy with 
submental, submandibular, cervical, inguinal, and axil-
lary involvement. He also exhibited abdominal distention 
with hepatosplenomegaly.
The initial laboratory examination was remarkable for a 
white blood cell count of 18,760 with 54 % lymphocytes, 
platelet count of 123,000, aspartate aminotransferase 
(AST) of 51 U/L, and alanine aminotransferase (ALT) of 
65 U/L. Haptoglobin was undetectable and lactate dehy-
drogenase was 743 U/L. HIV testing was performed sin-
gly and reactive by the Abbott Architect HIV antigen/
antibody 4th generation screening assay (Abbott Labora-
tories, Abbott Park, IL, USA). Confirmatory testing using 
the Multispot HIV-1 and HIV-2 antibody differentiation 
assay (Bio-Rad Laboratories, Redmond, WA, USA), how-
ever, was nonreactive and an HIV viral load was unde-
tectable. He had Epstein-Barr virus (EBV) viremia with 
4580 copies/mL detected. Computed tomography (CT) 
imaging of his neck demonstrated numerous bilateral 
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non-necrotic lymph nodes within the jugular chain, the 
largest of which measured 1.6  cm. CT of his abdomen 
and pelvis revealed extensive bulky adenopathy through-
out both the peritoneal and retroperitoneal spaces. An 
excisional biopsy was also performed on a submental 
lymph node which demonstrated florid follicular hyper-
plasia with interfollicular immunoblastic proliferation, 
hilar plasmacytosis, and an atypical T cell population, 
with some features of an angioimmunoblastic T-cell lym-
phoma. He had concurrent laboratory abnormalities that 
included positive rheumatoid factor, direct antiglobulin 
test, and hepatitis B IgM. Hepatitis B viral load was unde-
tectable. A CD4 count was 1042 cells/µL but represented 
only 10  % of T lymphocytes. Peripheral flow cytometry 
was performed with findings consistent with multiple 
T-cell phenotypic abnormalities, which were thought to 
represent a lymphoproliferative process versus polyclonal 
reactive process due to immune dysfunction.
After a multi-disciplinary review, the pathology of 
the biopsied lymph node was felt to represent reac-
tive changes with atypical lymphocytes secondary to 
EBV infection without clear evidence of a malignant 
lymphoproliferative disorder. He was seen on several 
occasions in follow-up, and ultimately returned to his 
previous state of health. CT imaging revealed sponta-
neous resolution of lymphadenopathy. EBV viral load 
became undetectable and platelet counts normalized. 
While the patient’s age and previous multiple sexual part-
ners made acute EBV infection less likely upon initial 
presentation, no alternative diagnosis was found.
Case 2
A 52 year old woman presented with 3 weeks of jaundice 
and increasing abdominal distension. The initial labora-
tory examination was remarkable for a white blood cell 
count of 24,000 with an absolute lymphocyte count of 
0, hemoglobin of 5.6 g/dL, platelet count of 83,000, and 
an international normalized ratio of 2.7 in the absence of 
anticoagulant medications. Her metabolic panel revealed 
a sodium of 124  mmol/L, total bilirubin of 4.2  mg/dL, 
and a mild increase in AST at 72 U/L.
A paracentesis was performed by the admitting physi-
cian. In the course of this procedure, the physician sus-
tained a cut from a scalpel visibly soiled with patient 
blood. Per facility protocol, testing for blood-borne path-
ogens was performed on the patient. Hepatitis B and C 
serologies were nonreactive. HIV testing was performed 
singly using the Abbott Architect p24 antigen/antibody 
assay which resulted in positive. Confirmatory testing by 
Multispot antibody differentiation was positive for HIV-1 
antibodies and negative for HIV-2 antibodies. On further 
interview, the patient denied a prior history of HIV test-
ing. She denied previous blood transfusions, intravenous 
drug use, or tattoos. She endorsed two lifetime male sex-
ual partners with inconsistent condom use.
Her initial blood sample arrived to the laboratory with 
two different patient labels, so HIV testing was repeated 
on the same day with a different venipuncture using the 
Abbott Architect p24 antigen/antibody assay and the 
same results returned. Additional testing revealed an 
absolute CD4 count of 116 cells/µL corresponding to 
61 % of her T lymphocytes and a CD4/CD8 ratio of 2.18. 
Potentially confounding conditions were evaluated yield-
ing a negative urine human chorionic gonadotropin, neg-
ative anti-nuclear antibody, and negative toxoplasma IgG 
and IgM. An HIV viral load showed no detectable RNA 
and a qualitative proviral DNA test was also negative. A 
Western blot was sent and returned as indeterminate due 
to nonspecific background reactivity.
Antiretroviral therapy was not initiated. CT of her 
abdomen showed innumerable peripherally enhancing 
and centrally necrotic hepatic lesions consistent with 
malignancy as well as enlarged retroperitoneal lymph 
nodes and spinal lesions consistent with metastases. 
A CEA and CA 19-9 were grossly elevated. The patient 
developed hemodynamically significant hematochezia 
requiring resuscitation with multiple units of blood prod-
ucts. She subsequently became hypoxic and hypoten-
sive and required intubation with pressor support. After 
discussion with her family, support was withdrawn, the 
patient died, and the family declined autopsy.
The physician who was exposed to blood was started 
on post-exposure prophylaxis with emtricitabine-teno-
fovir and raltegravir. His baseline Abbott Architect p24 
HIV antigen/antibody test (Abbott Laboratories, Abbott 
Park, IL, USA) performed singly on the same day as the 
aforementioned patient was reactive. As with the patient, 
the confirmatory Multispot antibody differentiation test 
which was drawn from a separate blood sample was also 
positive for HIV-1 but not HIV-2. An HIV viral load 
and qualitative proviral DNA test were both negative. 
He continued post-exposure prophylaxis for 1 week and 
then discontinued these medications. Follow up testing 
6 months after exposure was negative on both HIV anti-
gen/antibody test and proviral DNA.
In further review of specimen handling and process-
ing, the patient and physicians blood samples were not 
shipped to the facility laboratory together as they had 
distinct origins from the medical intensive care unit and 
emergency department respectively. Due to concerns for 
mislabeling of the patients initial blood sample, repeat 
testing was performed with a separate venipuncture 
which yielded the same results. Given the congruent lab-
oratory results from separate blood samples, no correc-
tive action reports were filed from the laboratory on that 
day.
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Discussion
We report the cautionary spectrum of false positive HIV 
diagnostics in three patients (Table 1). In case one, a false 
positive fourth generation test was not confirmed by anti-
body differentiation or by nucleic acid amplification test-
ing, representing a common scenario often observed with 
prior generations of HIV diagnostics. Yet, in case two, we 
report one likely and one confirmed false positive result 
which occurred with both the antigen/antibody assay and 
with a confirmatory HIV antibody differentiation test.
Following HIV transmission, markers of infection can 
be detected by diagnostic assays in a predictable fashion. 
An ‘eclipse phase’ typically lasting 10–14 days is charac-
terized by infection in local mucosal and lymphoreticu-
lar tissue during which systemic viremia is not detected. 
Approximately 7 days later, viral RNA becomes present in 
serum at quantities detectable by nucleic acid amplifica-
tion. Capsid protein p24 is the next chronological meas-
urable component of acute infection by way of detection 
of soluble antigen. Approximately 5 days after detection 
of p24 antigen, seroconversion occurs and anti-HIV anti-
body becomes evident by reactive results to various avail-
able ELISA assays [4, 5].
Various commercial fourth generation tests are avail-
able for use, all of which utilize the combined detection 
of p24 antigen and HIV-1/HIV-2 antibody. Ly et al. per-
formed a large analysis to investigate the sensitivity and 
specificity of various fourth generation tests. Numerous 
assays including the Abbott Architect p24 HIV antigen/
antibody test (Abbott Laboratories, Abbott Park, IL, 
USA) were able to detect infection prior to p24 antigen 
assays and in fewer than 3 days after nucleic acid testing 
while maintaining a specificity of greater than 99  % [6]. 
Fourth generation tests can effectively shorten the time 
frame in which HIV infection is undetectable prior to 
seroconversion. While reported sensitivity and specific-
ity of fourth generation tests remain higher than 99  % 
in numerous studies, several instances of discordance 
between screening and confirmatory techniques have 
been described [1, 7–10].
Lee et al. performed a comparative analysis of commer-
cially available 3rd and 4th generation screening assays 
in effort to evaluate the specificity and false positivity of 
the newer 4th generation assay [11]. Four seroconver-
sion panels were included for analysis including a batch 
of serum samples previously known to have produced 
discordant results between screening and confirmatory 
testing. Of the 54 known false positive serum samples, 
all 54 demonstrated continued discordance with 3rd gen-
eration testing, while 34 instances were reported with 
the 4th generation assay. Patients from whom discord-
ant samples were obtained also had various concurrent 
clinical conditions including rheumatologic diseases, 
viral hepatitis, malignancy, infection with Mycobacte-
rium tuberculosis, a history of multiple pregnancies, and 
recent Rickettsia infection, conditions which have been 
similarly associated with false positive screening tests in 
other studies [12–14]. Shida et al. describe a patient with 
a reactive 4th generation HIV diagnostic secondary to 
an angioimmunoblastic T-cell lymphoma [15], the lym-
phoproliferative disease originally suspected in “Case 1”. 
Various other phenomena were concurrently reported 
to cause false positive results including autoimmune 
hemolytic anemia, high anti-nuclear antibody titers, and 
a polyclonal hypergammaglobulinemia [15]. Importantly 
for roll-out of diagnostics for other HIV endemic coun-
tries, discordance between serologic screening tests and 
confirmatory assays have also been demonstrated in the 
setting of elevated IgG antibodies to Schistosoma species 
in a study of adolescents in Tanzania [16].
The new Multispot antibody differentiation test has 
been reported to have sensitivity and specificity greater 
than 99  % [17], comparing favorably with traditional 
Western blotting as a confirmatory assay [18]. Yet as Case 
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2 demonstrates, false positive results have been reported, 
more commonly with HTLV-I, HTLV-II, toxoplasmosis, 
and SLE [19]. It is biologically plausible that conditions 
which would yield a false-positive 4th generation anti-
gen/antibody assay could similarly cause a false posi-
tive antibody differentiation assay. Remarkably however, 
in Case 2, the false positive screening and confirmatory 
testing was observed not only for a patient with a likely 
malignancy but also for the healthcare worker with no 
known complicating health problems. This suggests that 
the etiology of the erroneous result may not have been 
intrinsic to the patient and, indeed, may have been sec-
ondary to reduced specificity of the batch of testing kits 
[17].
In 2014, the centers for disease control and preven-
tion (CDC) updated recommendations for the diagnosis 
of HIV infection to include a novel algorithm using the 
fourth generation screening and confirmatory assays [3]. 
Initial screening should begin with a combination immu-
noassay or fourth generation test that utilizes detection 
of both HIV-1/HIV-2 antibodies with HIV-1 p24 antigen. 
Negative results conclude testing, while reactive results 
necessitate further testing with a HIV-1/HIV-2 antibody 
differentiation assay. Specimens that demonstrate reac-
tivity on the initial screening immunoassay, but nega-
tive or indeterminate results on antibody differentiation 
assay, should undergo nucleic acid testing. In this report, 
the CDC algorithm guided the clinicians to the correct 
identification of a false positive test in Case 1. In the sec-
ond case, on the other hand, the algorithm would have 
led to two incorrect HIV diagnoses with the potential for 
substantial harm.
Conclusion
Rapid HIV diagnostics such as fourth generation antigen/
antibody assays and HIV antibody differentiation assays 
permit the identification of increased numbers of recent 
HIV infections and can help facilitate faster entry into 
care. While these testing modalities have high reported 
sensitivity and specificity, like all tests, they remain 
imperfect. CDC guidelines have been issued to assist cli-
nicians in the interpretation of these results, but these 
cases emphasize that correct use of the algorithm contin-
ues to require careful clinical judgment.
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